Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01475721 · ClinicalTrials.gov registry record · Phase 4
SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 11,751
- Enrollment target
NCT01475721 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 11,751 participants.
The verdict
NCT01475721, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11,751 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in adolescents and adults (12 years of age and older) taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone. ADVAIR™ and FLOVENT™ are trademarks of the GlaxoSmithKline Group of Companies.
Interventions
- DRUG ADVAIR 100/50mcg
- DRUG ADVAIR 250/50mcg
- DRUG FLOVENT 100mcg
- DRUG FLOVENT 250mcg
- DRUG ADVAIR 500/50mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,751 participants |
| Start Date | 2011-11-18 |
| Est. Completion | 2015-06-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01475721
The ClinicalTrials.gov registry entry for NCT01475721 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11,751 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ADVAIR 100/50mcg is the first listed.
NCT01475721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01475721 about?
NCT01475721 is a clinical study titled "SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.". The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in adolescents and adults (12 years of age and older) taking inhaled fluticasone propionate/salmeterol combination is the same as those tak...
What is the current status of trial NCT01475721?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11,751 participants. The study started on 2011-11-18. Estimated completion is 2015-06-23.
What interventions are being tested in trial NCT01475721?
The interventions under investigation include: ADVAIR 100/50mcg (DRUG), ADVAIR 250/50mcg (DRUG), FLOVENT 100mcg (DRUG), FLOVENT 250mcg (DRUG), ADVAIR 500/50mcg (DRUG).
Who is sponsoring clinical trial NCT01475721?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.